Healthy participation (ASA I and II) aged 18 or over undergoing single posterior implant treatment Benzydamine, Dental implant, Pain measurement, Analgesics
Conditions
Interventions
0.3% benzydamine hydrochloride was obtained from the manufacturing company.,The placebo used in the study was sourced from the same manufacturing company to guarantee uniformity in consistency, scent,
Active Comparator Drug,Placebo Comparator Drug
Benzydamine hydrochloride,Placebo
Sponsors
Intramural Research Fund, Faculty of Dentistry, Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with tooth loss for at least 3 months. Bone-level submerged implants were inserted under local anesthesia without premedication.
Exclusion criteria
Exclusion criteria: Smoking, allergy to BNZD and acetaminophen, regular use of medications affecting pain levels, need for bone or soft tissue augmentation, maxillary sinus augmentation, or pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain 3, 6, 18, 24, 48 hours after surgery Visual analoque scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Usage of spray 48 hours Times,Number of rescue analgesics 48 hours Number of pills | — |
Countries
Thailand
Contacts
Public ContactBoosana Kaboosaya
Faculty of Dentistry, Chulalongkorn University
Outcome results
None listed